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vABSTRACT
Volumetric modulated arc therapy (VMAT) is a rotational IMRT technique that uses a 
radiotherapy linear accelerator gantry with a dynamic MLC, variable dose rate, and variable 
gantry speed.  These new degrees of freedom of VMAT delivery introduced complexities for 
treatment planning, and Pinnacle3 SmartArc treatment module was recently developed as a 
solution.  However, it was unclear how varying each SmartArc parameter affected the resulting
plan quality.  The purpose of this study was to systematically examine all planning parameters 
and quantify the effect of varying each on the quality of a reference plan.
Parameters were separated into two categories: commissioning parameters and planning 
parameters.  Commissioning parameters were those available to the user during the machine 
commissioning process in Pinnacle, i.e. dose rate, gantry speed, MLC size, and MLC speed.  
Planning parameters were those available to the user during routine treatment planning, i.e. beam 
energy, collimator angle, arc length, and final gantry spacing.  A "baseline" set of commissioning 
and planning parameters was created that provided clinically acceptable plans for a cylindrical 
phantom case, simple prostate case, and complex (multi-target) prostate case.  Each parameter 
was independently varied while keeping all other parameters set to the baseline values.  The 
resulting change in each plan was evaluated using dose volume histograms, dose homogeneity 
indices (DHI), conformity indices (CI) and normal tissue dose metrics.
The DHI and CI for the phantom and simple prostate cases varied by less than 0.02 from 
the baseline values for most parameters.  The DHI and CI for the complex prostate case varied 
by more than 0.02 from the baseline values for most parameters.  The dose to normal tissues 
changed by less than 3% as parameters were varied for the simple prostate case and more than 
3% as parameters were varied for the complex prostate case.
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Most SmartArc parameters had little effect on DHI, CI, and normal tissue sparing for the 
phantom and simple prostate treatment geometries, but showed significant variations for the 
complex prostate case.  We conclude that SmartArc optimization is largely user-independent and 
hardware-independent for non-complex prostate treatment geometries.  However, certain 
parameters (especially planning parameters) create a significant change in resulting plan quality 
for complex prostate treatment geometries.  
11 INTRODUCTION
1.1 Background and Significance 
1.1.1 History and Development of VMAT 
Intensity modulated arc therapy (IMRT) is a radiation treatment modality that provides 
accurate, reliable, and highly conformal dose to a planning target volume (Khan 2003). Several 
techniques of delivering IMRT have been established: static-gantry techniques, such as fixed-
beam IMRT; and rotational-gantry techniques, such as helical tomotherapy (Mackie et al. 1993; 
Bortfeld and Webb 2009).  Fixed-beam IMRT has been shown to provide better dose 
conformality and normal tissue sparing than 3-D conformal treatments (Staffurth 2010), but it is 
still limited by only using a finite number of beams for delivery.  Helical tomotherapy also 
provides highly conformal dose distributions, but requires specialized delivery hardware and 
treatment planning software.  Both fixed-beam IMRT (except for compensator-based IMRT) and 
helical tomotherapy increase treatment delivery time compared to 3-D conformal treatments, 
which could lead to greater problems in dose accuracy due to intra-fractional motion.
The idea of using a traditional linear accelerator gantry for a rotational IMRT treatment 
was first suggested by Yu et al. in 1995 as an alternative to tomotherapy, which necessitated 
specialized equipment and struggled with abutment problems between treatment slices at that 
time.  Yu's alternative was called intensity modulated arc therapy (IMAT) and utilized a large 
field size, traditional linear accelerator, continuous gantry rotation, and dynamic MLC.   To 
create an intensity distribution, IMAT was delivered in multiple overlapping arcs.  Each arc 
delivered only one level of intensity; therefore multiple arcs were required for multiple levels of 
intensity.  The two-dimensional intensity distribution at each angle was a composition of 
multiple radiation fields of uniform intensity with different shapes and sizes.  Shortly after IMAT 
2was proposed, helical tomotherapy was created, alleviating abutment problems without the 
necessity of developing new software for optimization and delivery of IMAT.  As such, IMAT 
was never used in mainstream clinical practice.
Developments in rotational delivery capabilities of traditional linear accelerators in the 
last few years, specifically variable dose rate and variable gantry speed, have sparked a new 
interest in rotational IMRT delivery and IMAT (Bortfeld and Webb 2009).  Volumetric 
modulated arc therapy (VMAT) has been developed using the basic principles of IMAT, coupled 
with these new machine capabilities.  During a VMAT treatment, MLC leaves dynamically 
shape the beam to treat the entire volume of the planning target volume (PTV) with every 
rotation, and the dose rate and/or gantry rotation speed is continuously varied as the gantry of the 
linear accelerator rotates around the patient.  Because of the ability of the linear accelerator to 
vary dose rate and gantry speed during rotation, it is no longer necessary to use multiple 
overlapping arcs to create modulated intensity, and an entire fraction of treatment can often be 
delivered in a single arc (Bortfeld and Webb 2009).
Both Elekta, Inc. (Stockholm, Sweeden) and Varian Medical Systems (Palo Alto, 
California) have developed VMAT capabilities on their traditional linear accelerators.  Varian 
has named this new version of VMAT "RapidArc," while Elekta refers to it as "VMAT."  In this 
study "VMAT" is used as a generic term for a dynamic arc IMRT treatment modality that uses 
dynamic MLC, variable dose rate, and variable gantry speed, and is not meant to be vendor-
specific.  
1.1.2 Technical Description of VMAT 
Three key components of VMAT are rotational delivery, dynamic MLC, and variable 
dose rate and gantry speed.  To describe these components, it is useful to compare and contrast 
3VMAT to both fixed-beam IMRT and tomotherapy.  Although VMAT and tomotherapy are both 
rotational treatment modalities, their delivery methods are very different.  Tomotherapy, 
meaning ‘slice therapy,’ uses a fan beam and ring gantry to treat one transverse slice of the PTV 
at a time (Mackie et al. 1993).  In helical tomotherapy, much like helical computed tomography, 
the couch moves perpendicularly to the gantry plane while the gantry rotates around the patient, 
creating a spiral-treatment (Yang et al. 1997). With VMAT, however, the entire PTV is treated 
with every rotational pass of the gantry (Cao et al. 2007).  This means VMAT has the potential 
to treat the entire PTV to the desired dose using a single arc (Otto 2008).  In other words, 
tomotherapy can be considered a planar delivery technique, whereas VMAT is a volumetric 
delivery technique.  A schematic of the difference in delivery is shown in Figure 1-1.  Both 
gantries rotate around the patient, but the tomotherapy couch moves into the gantry to create a 
helical slice delivery while the VMAT couch remains stationary as the beam treats the entire 
PTV.
The next key component of VMAT treatments is the dynamic MLC.  Treatment plans for 
fixed-beam IMRT are comprised of a finite number of beams at fixed angles around the patient.  
Figure 1-1.  Tomotherapy slice delivery (left) vs. VMAT volumetric delivery (right).
4In order to produce an optimized fluence pattern for each fixed beam, the MLC leaves move 
either dynamically (Svensson et al. 1994) or in a step-and-shoot fashion (Wu et al. 2001) across 
the beam, creating several segments with different intensities to modulate the beam.  
Compensator-based IMRT does not use MLCs, but instead a tissue compensator is fabricated for 
every beam angle and attached to the machine before the beam is delivered.  In tomotherapy 
treatments, beams are optimized for 51 arc segments in each slice, and the binary MLC leaves 
are either open or closed for some specific amount of time during the arc segment in order to 
modulate the beam (Mackie et al. 1993).  For both fixed-beam IMRT and helical tomotherapy, 
the beam modulation is determined by the amount of time the leaves spend in each position.  
VMAT treatments must use a dynamic MLC because the beam is on during the entire treatment 
as the gantry rotates around the patient.  For VMAT treatments, the MLC leaves move as a 
Figure 1-2.  Sample MLC segments for VMAT delivery for 6 consecutive control 
points.  MLC leaves (white) do not simply follow the shape of the PTV (red) as the 
gantry rotates around the patient. 
5function of gantry position, not time (Bortfeld and Webb 2009).  The leaves reposition according 
to where the gantry is located in its rotation, and each angle of rotation sees only one segment 
shaped by the MLC.  However, because the leaves do not simply conform to the shape of the 
PTV, VMAT can still be considered a form of IMRT, not 3-D conformal therapy.  An example 
of MLC segment positions as the gantry travels around the arc is shown in figure 1-2.  The 
leaves are used to modulate the intensity distribution.
Rotational delivery adds the flexibility of treating at every angle, which can be greatly 
advantageous for some treatment sites, but the limited MLC range of motion per gantry angle 
somewhat limits this flexibility (Otto 2008).  Because the MLC leaves have a maximum speed, 
the distance they travel is limited by how slowly the gantry can rotate. Limited leaf motion and 
continuous beam delivery can quickly lead to unwanted dose to normal tissues.  To obtain a 
sufficient intensity resolution without the necessity of using overlapping arcs (Yu 1995; Earl et 
al. 2003), the dose rate and/or gantry speed are varied throughout the VMAT treatment.  This 
creates a direct modulation of beam output that is unique to VMAT delivery.  During VMAT 
treatment, the beam output is changed according to gantry position, whereas intensity modulation 
in both tomotherapy and fixed-beam IMRT results from changing the beam-on time for each 
MLC segment.  VMAT delivery combines varying leaf motion with varying dose rate and/or 
gantry rotation speed to modulate beam intensity.  
1.1.3 Advantages and Disadvantages of VMAT
The most frequently-mentioned and advertised benefits of VMAT are decreased 
treatment time and increased monitor unit (MU) efficiency.  If only a single arc is used, the 
beam-on time is reduced to the time it takes the gantry to rotate from the start angle to the stop 
angle position (including variations in gantry speed).  This can accomplish a substantially shorter 
6overall treatment time than both helical tomotherapy and fixed-beam IMRT (Webb and McQuaid 
2009).  It has been shown that for prostate and head and neck treatment sites, VMAT plans with 
similar or better quality than fixed-beam IMRT could be delivered in less than 3 minutes, 
compared to 8-12 minutes for fixed-beam IMRT delivery (Bzdusek et al. 2009; Verbakel et al. 
2009; Shaffer et al. 2009; Zhang et al. 2009).  The shorter overall treatment time has been 
advertised to lead to greater patient compliance as well as greater throughput for the radiation 
treatment facility.  Alternatively, shorter beam-on time may allow for use of more advanced
image-guidance tools, such as on-board cone beam computed tomography that is now becoming 
widely available, without sacrificing overall treatment time.  
VMAT also has much higher MU efficiency than other forms of IMRT delivery, with the 
exception of compensator-based IMRT.  This means VMAT can treat the PTV to the same dose 
using fewer MU than fixed-beam IMRT and helical tomotherapy.  Fixed-beam IMRT and 
tomotherapy keep the dose rate constant and change the amount of beam-on time for each MLC 
segment to modulate intensity.  With these techniques, much of the beam is “wasted” for small 
fields.  Because VMAT directly varies the dose rate of the beam to change the beam’s intensity, 
it is much more efficient in terms of MUs than both tomotherapy and fixed-beam IMRT.  
Verbakel et al. found that VMAT reduced the number of monitor units used per fixed-beam 
IMRT treatment by 40 percent for head and neck geometries (2009).  Bzdusek found MUs were 
decreased up to 23 percent for lung geometries, 13 percent for whole brain, and less than 10% 
for tonsil and prostate, where MU for one of three prostate cases actually increased 29 percent 
(2009).  Also, photon x-ray beams with energy less than 10MV are typically used for IMRT 
because IMRT treatments require more MUs than conformal treatments, causing increased 
secondary radiation to normal tissues outside the radiation field due to leakage and scatter.  For 
7energies greater than 10MV, neutron production from photon interactions in the machine head 
also increases with increasing MU (Reft et al. 2006).  By requiring fewer MUs, VMAT can 
potentially allow for usage of higher energy photons with reduced risk of secondary cancers.
Disadvantages of VMAT include a limited beam size, which makes VMAT incapable of 
treating long PTVs (e.g. craniospinal cases) without abutment of two arcs.  Also, multiple 
superimposed arcs may be required for VMAT to achieve comparable modulation and dose 
distributions to those achieved by Tomotherapy.  
1.2 Optimization of VMAT 
Along with the evolution of rotational delivery capabilities of the treatment machine, 
substantial changes in the optimization algorithms used for fixed-beam IMRT were necessary in 
order to make VMAT clinically possible.  These included techniques for creating an effective 
360 degree fluence map and the addition of several new optimization parameters.  The 
optimization module used in this study was SmartArc, developed for the Pinnacle3 treatment 
planning system (Philips Medical Systems, Andover, MA).
Though the beam treats in a continuous arc, there are a finite number of control points 
(CPs), or samples around the arc used for optimization and delivery.  This produces a tradeoff 
between dose delivery accuracy and optimization computation time (Otto 2008); more CPs leads 
to better plan accuracy but longer computation time.  Otto proposed implementing “progressive 
sampling” as a compromise.  First, coarse sampling is used to create intensity maps for several 
angles around the arc, and then subsequent CPs are added in smaller degree increments to 
increase plan dosimetric accuracy.  Figure 1-3 shows a diagram of progressive sampling.  
Bzdusek et al. (2009) incorporated progressive sampling in their VMAT optimization 
solution for the SmartArc treatment planning module.  First, an initial coarse sampling increment 
8of 24 degrees is used, and fluence maps are generated, optimized, and converted to leaf segments 
for these angles. Then, intermediate MLC segments are linearly interpolated between the coarse 
segments, creating a finer CP spacing (Bzdusek et al. 2009).  
SmartArc optimization module is outlined in Figure 1-4. First, intensity maps are 
optimized every 24 degrees around the arc and converted to 2-4 different MLC segments.  The 
Figure 1-3.  Diagram of progressive sampling. An initial coarse CP spacing is chosen (a) 
and intermediate CPs are added between existing CPs until desired CP frequency is 
reached (b-d).  Figure reprinted from Otto 2007, Medical Physics, Vol. 35 p 312
Figure 1-4.  Outline of SmartArc optimization.  Figure 
reprinted from Bzdusek et al. 2009, Medical Physics, Vol. 
36 p 2330
9two MLC segments that have the most open space are selected and redistributed 8 degrees above 
and below the point along the arc where the intensity map was initially created (every 24 
degrees).  The two segments with the most open space are selected in order to minimize leaf 
travel between CPs.  The remaining MLC segments generated for that point are discarded.  
Additional MLC segments are then linearly interpolated to create the CP resolution, or final 
gantry spacing, selected by the user (2, 3, 4, or 6 degrees).  Figure 1-5 shows the filtering, 
redistribution and sequencing of MLC segments.  
After initial arc MLC segments have been interpolated, machine parameters are 
optimized, followed by a convolution dose calculation and segment weight optimization.  Then 
the process is repeated until the number of iterations is reaches its limit.  The result is that every 
2, 3, 4, or 6 degrees, the treatment control system is given a new set of directions until it arrives 
at the next CP.  The set of directions includes MLC configuration, leaf speed, dose rate and 
gantry rotation speed.
Figure 1-5.  Diagram of MLC segment creation for SmartArc 
optimization.  2-4 segments are generated at the initial CP spacing 
(24º), then 2 are selected and redistributed (crosses) while the 
others are discarded.  Additional MLC segments are interpolated 
between the initial segments (first blue circles, then red).  Figure 
reprinted from Bzdusek et al. 2009, Medical Physics, Vol. 36 p 2330
10
1.3 Motivation for Research
Clinical treatment planning requires commercialized software and tested protocols to 
accurately construct radiation therapy treatment plans that maximize the capabilities of available 
technology.  While such tools have long been established for tomotherapy and fixed-beam 
IMRT, analogous tools for VMAT are still in the development stages.  Recently a commercial 
utility, Phillips Pinnacle3 SmartArc (described above), has been created to optimize VMAT 
treatments; however, the optimization process contains numerous parameters and options that 
have not yet been fully explored (Bzdusek et al. 2009).  It is currently unknown how each of 
these parameters may be used to generate an optimal treatment plan for any particular treatment 
site.  
The goal of this study was to systematically vary and examine new parameters introduced 
by VMAT (such as variable dose rate) and previously existing parameters (such as maximum 
gantry speed) that had potential to influence resulting VMAT plans.  A comprehensive study of 
all parameters related to VMAT treatment planning is clinically relevant and useful for future 
treatment planning.
1.4 Hypothesis and Specific Aims
Our hypothesis was that a set of parameters for the Phillips Pinnacle3 SmartArc treatment 
planning module could be determined that produce dynamic arc plans with 
1) treatment times less than half that of corresponding fixed-beam IMRT plans, and 
2) better than !3% dose homogeneity in the PTV of a water phantom, !5% dose 
homogeneity in the PTV of a simple prostate patient, and !5% dose homogeneity in the 
primary PTV of a multi-target complex prostate patient
while maintaining sufficient sparing of critical structures.  
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Specific Aim 1:  Determine a set of baseline parameters for planning VMAT 
treatment for a spherical PTV in a simple water-equivalent phantom, and then vary 
parameters systematically.  The baseline plan was considered acceptable if it maintained !3% 
dose homogeneity within the PTV.  All parameters were kept identical to the baseline set except 
the parameter actively being studied.
Specific Aim 2: Determine a set of baseline parameters for planning VMAT 
treatment for a simple prostate patient, and then vary parameters systematically.  A 
previously treated, simple prostate patient involving a single target was selected.  The baseline 
plan was considered acceptable if it maintained !5% dose homogeneity within the PTV and 
sufficiently spared surrounding critical structures.
Specific Aim 3: Determine a set of baseline parameters for planning VMAT 
treatment for a complex, multi-target prostate patient, and then vary parameters 
systematically.  A previously treated, complex prostate patient involving multiple targets was
selected.  The baseline plan was considered acceptable if it maintained !5% dose homogeneity 
within the PTV and sufficiently spared surrounding critical structures.
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2 METHODS
To determine how optimization parameters affect resulting plan quality, parameters were 
varied and resulting plans evaluated for three treatment sites with increasing complexity.  All 
cases were planned and optimized using Pinnacle3 version 8.1y (Philips Medical Systems, 
Andover, MA). Version 8.1y was the first release of Pinnacle to include the SmartArc planning 
module, and it was the most current version at the time of the study.  All parameters used in this 
study are introduced here, followed by a detailed description of the methods common to all 
specific aims and, finally, an explanation of details unique to each specific aim.
2.1 Description of Parameters
2.1.1 Commissioning Parameters
A list of parameters relevant to SmartArc planning was created and categorized into two 
groups: commissioning parameters and planning parameters.  Commissioning parameters were 
those parameters available for selection during the commissioning and configuration of the linear 
accelerator in the treatment planning system.  These parameters included dose rate, gantry speed, 
MLC size and maximum leaf speed, and maximum MU per degree of rotation.  These 
parameters are typically chosen based on the physical and mechanical capabilities of the linear 
accelerator used for treatment, and are briefly described here:
" Dose rate is a measure of the output of the beam in MU per time.  The Philips Pinnacle 
treatment planning system allows for the dose rate to be varied either continuously or 
discretely.  The user must also specify a maximum allowable dose rate.  If the dose rate is 
varied continuously, the user must only provide the maximum allowable dose rate as 
input to Pinnacle.  If the dose rate is varied discretely, the user must provide each 
allowable dose rate in a table provided in the commissioning window of Pinnacle.  Elekta 
linear accelerators vary dose rate discretely, stepping down from the maximum dose rate 
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by a factor of two until reaching some minimum dose rate (i.e. 600, 300, 150, 75, 37 
MU/min).  Varian linear accelerators, however, have a continuously variable dose rate.  
In this study, trials for both continuously variable and discretely variable dose rates were 
examined for maximum dose rates of 400, 600 and 800 MU/min.
" Maximum gantry speed describes the maximum angular velocity of the gantry, and is 
given in units of degrees per second.  The maximum gantry speed would theoretically 
influence resulting VMAT plans because the gantry is continuously rotating as the beam 
is continuously delivering.  A faster maximum speed implies the possibility of a shorter 
overall delivery and perhaps a better dose distribution.  The faster gantry lowers the 
minimum possible dose delivered per control point arc.  Maximum gantry speeds of 4, 6, 
8, and 12 deg/sec were used in this study.
" Maximum MLC leaf speed is a measure of how far the leaves can travel in a certain 
amount of time in units of cm/sec.  The relevance of this parameter is connected to gantry 
rotation speed.  The distance the leaves can travel per gantry rotation determines how 
much the beam shape can change between control points, and how much the beam can be 
modulated by the MLC.  Only IMRT delivery techniques using dynamic MLC would be 
influenced by this parameter.  Maximum MLC leaf speeds used in the study were 1, 2, 
and 3 cm/sec.
" MLC leaf size describes the width of the individual MLC leaves and varies among linear 
accelerator vendors.  Leaves in the 80-leaf MLC of Elekta linear accelerators have 1cm 
thickness, while the 120-leaf Varian MLC combines 5mm leaves in the center of the field 
with 1cm leaves toward the edges of the field.  It would be intuitive to assume a smaller 
MLC leaf size would produce a more conformal dose to the PTV and spare normal 
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tissues surrounding the PTV more effectively.  In fact, it has been shown that this is not 
necessarily the case for fixed-beam IMRT (Su et al. 2007).  Leaf widths of 1cm and 5mm 
were both used in this study.
" Maximum MU/degree limits how much output the beam can deliver per degree of 
rotation.  The starting value for this study was 100 MU/deg, and then 1 MU/deg was 
chosen to determine how the optimization algorithm would respond to an unreasonably 
low value.
Commissioning parameters do not necessarily have an effect on optimization of fixed-beam 
IMRT treatments.  For example, the leaf speed and gantry rotation do not affect the plan quality 
of a step-and-shoot treatment because the leaves are not moving and the gantry is not rotating 
while the dose is being delivered.  However, commissioning parameters could have an important 
influence on plan quality for VMAT treatments because the gantry rotates and the MLC moves 
continuously during beam delivery.  A list of commissioning parameters and the range of values 
for which each parameter was varied is given in Table 2-1.  The intervals of values chosen for 
parameter variation were selected to bind the possible capabilities of a linear accelerator around a 
Table 2-1.  List of commissioning parameters and range 
of values used in the study.  Baseline values shown in 
bold type.
Commissioning Parameters Range of values
Gantry Speed Variability yes/no
Maximum Gantry Speed 4, 6, 8, 12 deg/sec
Maximum Dose Rate 400, 600, 800 MU/min
Dose Rate Variability Continuous/Discrete
Maximum MLC Leaf Speed 1, 2, 3 cm/sec
MLC Leaf Size 1cm/5mm
Maximum MU/degree 1, 100 MU/deg
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baseline value, shown in bold type in Table 2-1.  Baseline values were chosen according to 
recommendations from Pinnacle (Friberger 2009) and existing machine capabilities.  
2.1.2 Planning Parameters
Planning parameters were defined as those parameters available for selection during 
routine treatment planning.  Planning parameters examined in this work included beam energy, 
arc length, collimator angle, dose grid resolution, final gantry spacing, and maximum delivery 
time, and are briefly described here:
" Beam energy depends on a selection of megavoltage energies available for any specific 
machine.  The machine used in the present study had 6, 10, and 15 MV energies 
available.
" Arc length is determined by setting the start and stop angle of the continuous arc.  
Pinnacle version 8.1y used in this study could only optimize for a single, maximum 360-
degree arc.  For this study, total arc lengths were varied to 60, 120, 180, 270, and 360 
degrees.
" Collimator angle ranges from 0 to 360 degrees and remains stationary throughout the 
entire treatment.  MLC leaves move in only one dimension, so the collimator can move 
parallel to gantry rotation direction (90 degree collimator angle for this study) or 
perpendicular to gantry rotation direction (0 degree collimator angle  for this study) or at 
some angle in between.  A 45 degree collimator angle covers the longest distance in the 
superior-inferior dimension.  Collimator angles of 0-90 degrees represent a complete 
range of collimator orientations with respect to gantry rotation direction.  For instance, 
collimator angles of 0 and 180 degrees represent the same orientation to gantry rotation, 
and collimator angles of 90 and 270 degrees represent the same orientation to gantry 
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rotation.  For this reason, only collimator angles ranging from 0 to 90 degrees were used 
in this study.
" Dose grid resolution determines the dose calculation sampling resolution for the Pinnacle 
treatment planning system.  The standard dose grid resolution used in our treatment 
facility is 0.400 cm.  Dose grid resolution was also varied to 0.300cm and 0.500 cm to 
determine the effects on resulting plan quality.
" Final gantry spacing is the final spacing of control points around the VMAT delivery arc.  
Because of progressive sampling, described earlier, the optimization always starts at a 24 
degree spacing of control points, and the final spacing is chosen by the user to be 2, 3, 4, 
or 6 degrees.
" Maximum delivery time is requested by the user to keep overall treatment time less than 
some maximum value.  Maximum delivery times used in this study were 60, 120, and 
240 seconds for all treatment geometries, with varying supplemental treatment times for 
each geometry.
" Allow backup jaw motion parameter determines if the jaws remain stationary or if they 
are allowed to follow the MLC leaves during treatment.  Allowing back-up jaw motion 
during optimization created an artifact in the computed final dose in version 8.1y, so jaws 
were opened enough to cover the PTV with a 0.5cm margin from all gantry angles at 
specified collimator setting and fixed in position for optimization for this study.  In more 
recent versions of Pinnacle (9.0), this problem has been resolved.  
Planning parameters are not necessarily limited by linear accelerator capabilities, but are an 
integral part of the optimization process for SmartArc treatment planning.  They are typically 
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variable within the machine’s capabilities and chosen by the planner to create the best possible 
plan.  
In addition to planning parameters used for several different delivery techniques, there 
are a few planning parameters specific to SmartArc optimization.  One of these parameters, final 
gantry spacing, determines the final spacing of control points around the delivery arc.  Maximum 
delivery time is also unique to SmartArc optimization and allows the user to minimize overall 
treatment time per treatment fraction.  A complete list of planning parameters used in this study 
and the interval of values for which they were varied is given in Table 2-2.  Baseline values are 
shown in bold type.  These values were chosen according to recommendations by Pinnacle and 
common values used for fixed-beam IMRT in our treatment facility.
2.2 Research Design
This study focused on three treatment sites to determine the effect of varying each of the 
previously mentioned parameters on plan quality: a spherical target within a cylindrical phantom, 
a single-target prostate, and a multi-target prostate.  Each of the three specific aims tested the
hypothesis for one and only one of these treatment sites.  The process for creating treatment 
plans and evaluating commissioning and planning parameters was common to all aims and is 
described in the following paragraphs.  First, a clinically acceptable baseline plan was generated 
for each treatment geometry.  Then, parameters were varied independently and systematically
Table 2-2.  List of planning parameters and range of 
values used in this study.  Baseline values are shown in 
bold type.
Planning Parameters Range of values
Beam Energy 6, 10, 15 MV
Arc Length 60, 120, 180, 270, 360 deg
Collimator angle 0, 30, 45, 60, 90 deg
Dose grid resolution 0.3, 0.4, 0.5 cm
Maximum delivery time 60, 120, 240 sec
Final gantry spacing 2, 3, 4, 6 deg
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from their baseline values. Finally target homogeneity data, conformity data, and normal tissue 
data were collected in order to quantify and evaluate the quality of resulting plans.
2.2.1 Baseline Plan
For each treatment site, a baseline plan was created that provided acceptable dose 
homogeneity and sufficient normal tissue sparing.  To determine sufficient normal tissue sparing 
and clinical acceptability, all baseline plans were approved by a radiation oncologist.  Initial 
parameter values for each baseline plan were set based on recommendations from Pinnacle or 
taken as values from an Elekta linear accelerator used for IMRT treatment at our facility.  
Baseline parameter values are shown in Table 2-3.
2.2.2 Parameter Variation
Once a baseline plan was created, all commissioning and planning parameters were 
varied systematically.  Figure 2-1 shows a diagram of how each parameter was varied.  After the 
treatment geometry was selected and the baseline parameter values were chosen, the baseline 
Table 2-3. Baseline parameter values for all three 
treatment geometries.
Parameter Baseline Value
Gantry Speed Variability yes
Maximum Gantry Speed 6 deg/sec
Maximum Dose Rate 600 MU/min
Dose Rate Variability Discrete
Maximum MLC Leaf Speed 2 cm/sec
MLC Leaf Size 1cm
Maximum MU/degree 100 MU/deg
Beam Energy 6 MV
Arc Length 360 deg
Collimator angle 0 (prostate), 90 (phantom) deg
Dose grid resolution 0.4 cm
Maximum delivery time 120 sec
Final gantry spacing 4 deg
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plan was copied several times, creating a new plan for each parameter in order to study 
parameters separately.
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Figure 2-1. Diagram of steps taken to create new trials for each parameter studied.  First 
patient geometry is selected, then a baseline plan is created and copied several times to create a 
new plan for each parameter studied.  The baseline trial is then copied within each plan in order 
vary that parameter while keeping all other parameters set to their baseline values.
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Several trials were created within each plan corresponding to different input values for 
that parameter.  For example, a plan entitled “Maximum gantry speed” was created for each 
patient, and several trials were created inside that plan with different maximum gantry speeds.  
To examine commissioning parameters, it was necessary to commission a new machine for each 
trial.  
Copying the baseline plan generated a baseline trial within every plan.  Each parameter 
was varied from a copy of this baseline trial.  In other words, the baseline plan was copied 
several times to create new plans (one plan for every commissioning and planning parameter), 
and the baseline trial was copied several times to create new trials within those plans.  This 
assured that all parameters remained fixed at the baseline values except for the parameter being 
studied in that plan.  The number of trials in each plan depended on the range of variability of the 
parameter being studied.  Some parameters consisted of a yes or no option; therefore these plans 
contained only two trials.  The range of variability was chosen to expand above and below the 
baseline value for each parameter, and is shown for commissioning and planning parameters in 
Tables 2-1 and 2-2.  Table 2-1 shows 6 commissioning parameters with 16 unique settings, and 
Table 2-2 shows 6 planning parameters with 23 unique settings.  For this study, parameters were 
varied independently to determine their individual effect on resulting plan quality, as varying all 
combinations of parameters (almost 800,000 possibilities) together would be impractical using a 
systematic approach.
2.2.3 Plan Evaluation
Plans from each trial were compared and evaluated using the dose volume histograms 
(DVHs) calculated by Pinnacle, the dose homogeneity index (DHI) for each PTV, the conformity 
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index (CI) for the primary PTVs of each treatment geometry, and the dose to normal tissue 
metrics.  The DHI was calculated as
D
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where Dmin(99%) is the dose exceeded by 99% of the target volume and Dmax(1%) is the dose 
exceeded by  1% of the target volume. This was done in order to avoid including artificially 
high and low dose regions created by Pinnacle’s dose computation and/or small volumes of little 
clinical interest.  A perfectly homogenous dose to the PTV would result in a DHI of 0.0.  The 
conformity index (CI) was also used to evaluate the quality of each plan.  The conformity index 
measures how well the prescription dose conforms to the target volume, and it is defined as
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where PIV is the volume covered by the prescribed isodose value, TV is the volume of the target, 
and TVPIV is the volume of the target within the prescribed isodose value.  Ideally the PIV, TV, 
and TVPIV would be equal, making the CI equal to 1.  
For the two cases involving normal tissue constraints (simple prostate and complex 
prostate), normal tissue metrics were also used to evaluate the plan quality.  “Hard” constraints 
for normal tissues for intact prostate cancer treatment are described by Pollack et al. (2005): 
!"#$%&'(%!)*$%+,%-./%0/1-&2%3+245/%0/1/63/7%89*:;%&'(%8<=:;>%0/7?/1-63/2;@%!A*$%&'(%!*=$%
of the bladder volume receives 89*:;%&'(%8<=:;>%0/7?/1-63/2;@%&'(%!"=$%+,%/&1.%,/5+0&2%./&(%
receives 8*=:;B%%C'/%+,%-./%&D7+24-/%1+'(6-6+'7%,+0%126'61&2%&11/?-&D626-;%+,%-./se prostate plans 
was that 95% or greater of the PTV received 100% of the prescribed dose.  For this reason, all 
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prostate plans in our study were normalized so that 95% of the PTV received the prescription 
dose.  Normal tissue metrics were taken from Pollack et al., and evaluated at 17% and 35% of 
the rectum, 25% and 50% of the bladder, and 10% of the femoral heads.  The maximum dose to 
the femoral heads were also evaluated, taken at Dmax(1%).  The phantom case had no normal tissue 
constraints, so only the DHI and CI were used in evaluating parameter trials for the phantom 
case.
2.3 Specific Aims
Three treatment geometries of increasing complexity were chosen for this study in order 
to determine the effect of varying both commissioning and planning parameters on resulting plan 
quality.  Each specific aim examined a single treatment geometry.  The following sections
describe the details unique to each specific aim.  
2.3.1 Specific Aim 1: Phantom Case
The first geometry, a phantom, was chosen to represent an ideal case for treatment.  
Because it was important to start with the simplest conceivable case to determine an upper 
threshold for the capabilities of SmartArc optimization, the phantom geometry can be described 
as a simple approximation of a prostate PTV without any dose limiting structures.  For the 
phantom geometry, a spherical target was contoured in the center of a cylindrical, homogeneous, 
water-equivalent phantom.  The target was 7.5 inches in diameter, and it was centered inside the 
30-inch diameter cylinder.  A cylindrical phantom was chosen instead of a rectangular phantom 
because it was believed to better represent the contour of the human body.  The spherical target 
was drawn using Pinnacle software in the center of the phantom, and there were no avoidance 
structures identified.  The prescription given to the phantom target for optimization was 200 cGy 
to 95% of the PTV in 1 fraction, which represents a typical fractional dose for prostate cancer at 
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our treatment facility.  Because the tabular DVHs calculated by Pinnacle show dose in cGy, the 
phantom plans were later prescribed 7600 cGy in 38 fractions to achieve a better dose resolution 
for gathering data from the DVHs.  Changing the number of fractions in the prescription did not 
change the fractional DVH; all data points were merely multiplied by a factor of 38.  A 
transverse view of the phantom geometry is shown in Figure 2-2.
2.3.2 Specific Aim 2: Simple Prostate Case
The second geometry was a single-target prostate patient.  This case was chosen because 
it represented a relatively standard, simple prostate case.  The patient selected had previously
been treated at our facility with fixed-beam, 7-field step-and-shoot IMRT.  The original 
prescription was 7600 cGy to the PTV in 38 fractions delivered with a 6MV beam, and 
avoidance structures included the rectum, bladder, and left and right femoral heads.  The 
prescription for this study was kept the same as the original prescription.  Transverse, sagittal, 
and coronal views of the simple prostate geometry are shown in Figure 2-3.
Figure 2-2.  Transverse view of phantom 
case.  PTV is shown in red.
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2.3.3 Specific Aim 3: Complex Prostate Case
The third geometry used in this study was a complex prostate case with multiple PTVs.  
This treatment site was chosen to represent a more complicated geometry.  The patient was 
previously treated at our facility with helical tomotherapy.  The original prescription was 56 Gy 
in 28 fractions to the extended prostate bed with a 22 Gy boost to the prostate bed; 61.6 Gy in 28 
fractions to a positive node; and 46.2 Gy in 28 fractions to the entire nodal region. Avoidance 
structures included the rectum, bladder, and left and right femoral heads.  The prescription for 
the SmartArc optimization was 78 Gy to the prostate bed (PTV 1), 61.6 Gy to the positive node
(PTV 2), 56 Gy to the extended prostate region (PTV 3), and 46.2 Gy to the extended nodal 
region (PTV 4) in 28 fractions.   Transverse, sagittal, and coronal views of the complex prostate 
treatment geometry are shown in Figure 2-4.
   
Figure 2-3.  Transverse (top), sagittal (left), and coronal (right) view of simple prostate 
case.  PTV is shown in red.
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Figure 2-4.  Transverse (top), sagittal (left), and coronal (right) views of complex 
prostate geometry.  PTV1: red, PTV2: green, PTV3: blue, PTV4: orange.
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3 RESULTS
This chapter describes the resulting plans based on metrics taken from the dose volume 
histograms (DVHs), dose homogeneity indices (DHI), conformity indices (CI), and normal tissue 
metrics. The results for the three baseline plans are described first, and then data for each 
commissioning and planning parameter is presented simultaneously for all three specific aims.
3.1 Baseline Results
3.1.1 Phantom Baseline Results
A baseline plan was created to achieve acceptable dose homogeneity to the target for the 
phantom case.  A transverse image of the baseline plan is shown in Figure 3-1, where the red 
shaded area represents the PTV.  The corresponding DVH for the phantom baseline plan is 
shown in Figure 3-2.  A single, 360-degree dynamic arc beam with energy 6MV was used for the 
baseline plan, and the isocenter for this beam was placed in the center of the target volume.  The 
plan was allowed 35 iterations, but a solution was found in only 21 iterations.  The convolution 
dose calculation started at iteration 8.  The only optimization objectives set for this aim, listed in 
Table 3-1, were maximum and minimum dose to the PTV.  The prescription isodose line 
(7600cGy) is shown in Figure 3-1, along with the prescription ±3% isodose lines (7372cGy and 
7828cGy).  All baseline commissioning and planning parameter values were discussed 
previously and are shown in Table 2-3.  All trials were normalized so that at least 95% of the 
PTV received 100% of the prescribed dose.  The optimization took approximately 15 minutes for 
each trial (excluding smaller arc lengths) for the phantom case, and final dose computation took 
about 20 minutes to complete for each trial.
       Table 3-1.  Optimization objectives for phantom case, Aim 1
ROI Type Target cGy Weight
PTV Max Dose 205 10
PTV Min Dose 195 10
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3.1.2 Simple Prostate Baseline Results
A baseline plan was created to achieve ±5% dose homogeneity to the simple prostate 
target.  A single, 360-degree dynamic arc beam with an energy of 6MV was used for the baseline 
plan, and the isocenter for this beam was placed in the center of the prostate PTV.  The 
optimization was allowed 45 iterations, with the convolution dose calculation starting at iteration 
Figure 3-1.  Phantom baseline plan isodose lines (blue: 97%, 
yellow: 100%, green: 103% of prescribed dose)
Figure 3-2.  DVH for the phantom baseline plan.  PTV: 
red, no avoidance structures.
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8.  Figure 3-3 shows a transverse slice of the baseline plan for the simple prostate patient 
including isodose lines for the prescription dose (7600cGy) and ± 5% of the prescription dose 
(7372cGy and 7828cGy).  Optimization objectives for the simple prostate case were kept very 
similar to the optimization objectives of the original plan with only minor tuning in order to 
reach homogeneity goals.  A complete list of optimization objectives for the simple prostate case 
Table 3-2. Optimization objectives for simple prostate case, Aim 2
ROI Type Target cGy % Volume Weight
PTV 76 Max dose 7800 - 10
PTV 76 Min dose 7300 - 10
PTV 76 Min DVH 7600 95 45
76 only Max dose 7600 - 1
Ring Max dose 3800 - 1
Rectum Max DVH 3500 45 1
Rectum Max DVH 7000 8 1
Rectum Max DVH 6500 15 1
Bladder Max DVH 4000 45 1
Bladder Max DVH 6000 20 1
LFH Max dose 4300 - 1
RFH Max dose 4300 - 1
Figure 3-3.  Simple prostate baseline plan isodose lines 
(blue: 95%, yellow: 100%, green: 105% of prescribed 
dose)
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is given in Table 3-2.  All baseline commissioning and planning parameter values for the simple 
prostate case were discussed previously and are shown in Table 2-3.  After the baseline plan was 
created, the DVH for the plan, shown if Figure 3-4, was approved by a radiation oncologist.  It 
was determined that the baseline plan was clinically acceptable for treatment based on dose 
homogeneity to the target volume and normal tissue constraints.  All trials were normalized so 
that at least 95% of the PTV received 100% of the prescribed dose.  The optimization took 
approximately 40 minutes for each simple prostate trial (excluding smaller arc lengths), and final 
dose computation took roughly 50 minutes to complete for each trial.
3.1.3 Complex Prostate Baseline Results
A baseline plan was created for the complex prostate case, attempting to achieve ±5% 
dose homogeneity to the primary PTV.  This homogeneity goal was not achieved, and the better 
of two possible baseline plans was chosen by a radiation oncologist.  Figure 3-5A and 3-5B show 
transverse and saggital views of the patient where all 4 PTVs are visible.  The prostate bed
Figure 3-4.  DVH for the simple prostate baseline plan.  
PTV: red, rectum: brown, bladder: yellow, right femoral 
head: purple, left femoral head: blue.
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is shown in red (PTV 1; 7800 cGy), the extended prostate shown in dark blue (PTV 3; 5600
cGy), the positive node in purple (PTV 2; 6160 cGy), and the extended nodal region in light blue 
(PTV 4; 4620 cGy).  Figure 3-6 shows the DVHs for all PTVs and critical structures for the 
complex prostate case.  A single, 360-degree dynamic arc beam with energy 6MV was used for 
Table 3-3.  Optimization objectives for complex prostate case, Aim 3
ROI Type Target cGy % Volume Weight
PTV 78 Max Dose 7900 - 100
PTV 78 Min Dose 7600 - 100
PTV 78 Uniform Dose 7800 - 100
7800 ring Max Dose 7800 - 1
PTV 6160 Uniform Dose 6160 - 75
6160 ring Max Dose 6160 - 1
PTV 56 Min DVH 5600 95 1
5600 only Uniform Dose 5600 - 1
PTV 4620 Min DVH 4620 95 30
4620 only Uniform Dose 4620 - 25
Ring 1 Max Dose 3500 - 1
Rectum Max DVH 6500 17 20
Rectum Max DVH 4000 35 30
Bladder Max DVH 6500 25 20
Bladder Max DVH 4000 50 20
LFH Max Dose 4200 - 40
RFH Max Dose 4200 - 40
Figure 3-5.  Complex prostate baseline plan transverse (A) and sagittal (B) views.  
Shaded areas represent PTVs, and corresponding lines represent 100% of the 
prescribed dose for each PTV.  PTV1 (7800cGy): red, PTV2 (6160cGy): blue, PTV3 
(5600cGy): green, PTV4 (4620cGy): orange.
A B
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the baseline plan, and the isocenter was placed in the center of the composite target volumes.  
The plan was allowed 35 iterations, with the convolution dose starting at iteration 10.  
Optimization objectives for the complex prostate case baseline plan are shown in Table 3-3.  
Because the patient was previously treated with helical tomotherapy, there was no previous set of 
optimization objectives for the Pinnacle treatment planning system.  Optimization objectives and 
additional regions of interest (such as rings) were created to achieve a clinically acceptable 
baseline plan.  The baseline plan for the multi-target prostate case was determined to be 
clinically acceptable by a radiation oncologist, though the "hard" normal tissue constraints
described by Pollack et al., for the most part, were not met.  The baseline set of parameters was 
identical to the single-target prostate case.  Baseline commissioning and planning parameters are 
shown in Table 2-3.  
All trials were normalized so that at least 95% of the PTV received 100% of the 
prescribed dose.  The optimization took approximately 45 minutes for each complex prostate 
A B
Figure 3-6.  DVH for the complex prostate baseline plan.  
PTV1: red, PTV2: dark blue, PTV3: green, PTV4: orange, 
rectum: brown, bladder: yellow, right femoral head: purple, 
left femoral head: light blue.
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trial (excluding smaller arc lengths), and final dose computation took roughly 80 minutes to 
complete for each trial.
3.1.4 Baseline DHI and CI Values
Values of DHI , CI, and normal tissue metrics for the baseline plans are shown in Tables 
3-1 to 3-3. DHI was lowest for the phantom case and highest for the PTVs of the complex 
prostate case.  CI was highest for the simple prostate case and lowest for the complex prostate 
case.  It is believed that CI performed better for the simple prostate case than the phantom case 
because the phantom case had no avoidance structures.  Normal tissue sparing was better for the 
simple prostate case than the complex prostate case.  
Table 3-4.  Baseline values for DHI, Dmax, and Dmin for PTVs of the three treatment 
geometries, shown in cGy.
Geometry (Dose Rx to 95% PTV) PTV Dmin(99%) PTV Dmax(1%) DHI
Phantom (76 Gy) 7540 7812 0.0358
Simple Prostate (76 Gy) 7447 8006 0.0736
PTV 1 (78 Gy) 7481 8744 0.1619
PTV 2 (61.6 Gy) 6133 6918 0.1274
PTV 3 (56 Gy) 5333 8721 0.6050
PTV 4 (46.2 Gy) 4047 7456 0.7379
Table 3-5.  Baseline values for CI for the three treatment geometries.
Geometry CI
Phantom 0.8777
Simple Prostate 0.9106
Complex Prostate (PTV1) 0.7900
Table 3-6.  Baseline values for normal tissue metrics for prostate geometries, shown in cGy.
Geometry
Rectum Bladder Rt. Fem. Head Lt. Fem. Head
D17 D35 D25 D50 D10 Dmax(1%) D10 Dmax(1%)
Simple Prostate 5297 3893 4420 1927 3702 3927 3855 4248
Complex Prostate 6666 5066 6054 4811 4250 4748 4477 4868
Pollack et al. (2008) limit 6500 4000 6500 4000 5000 -- 5000 --
33
3.2 Commissioning Parameters
3.2.1 Gantry Speed Variability
DHI, CI, and normal tissue values for gantry speed variability are shown in Tables 3-4
and 3-5.  The DHI showed no change for the phantom and complex prostate cases and varied less 
than 2% for the simple prostate case.  In fact, the phantom and complex prostate cases showed 
identical plans for both trials, and the simple prostate case showed little difference in the
resulting plans.  
The CI showed no change for the phantom and complex prostate cases and differed by 
less than 0.03 between trials for the simple prostate case.  
Table 3-7.  DHI and CI values for Gantry Speed Variability (PTV 1: 78Gy, PTV 2: 
61.6Gy, PTV 3: 56Gy, PTV 4: 46.2Gy).
Dose Homogeneity Index
Gantry Speed Phantom Simple Prostate
Complex Prostate
PTV 1 PTV 2 PTV 3 PTV 4
Variable (max 6 deg/sec) 0.0358 0.0736 0.1619 0.1274 0.6050 0.7379
not variable (6 deg/sec) 0.0358 0.0866 0.1619 0.1274 0.6050 0.7379
Conformity Index
Gantry Speed Phantom Simple Prostate Complex Prostate
Variable (max 6 deg/sec) 0.8777 0.9106 0.7900
not variable (6 deg/sec) 0.8777 0.8956 0.7900
Table 3-8.  Normal tissue metrics for Gantry Speed variation for simple and complex 
prostate cases.  All normal tissue dose metrics are shown in cGy.
Gantry 
Speed
Norm. 
%
Rectum Bladder Rt. Femoral Head Lt. Femoral Head
D17 D35 D25 D50 D10 Dmax(1%) D10 Dmax(1%)
Simple Prostate
variable 95.4 5297 3893 4420 1927 3702 3927 3855 4248
not variable 95.4 5371 3955 4458 1906 3767 4023 3820 4209
Complex Prostate
variable 95 6666 5066 6054 4811 4250 4748 4477 4868
not variable 95 6666 5066 6054 4811 4250 4748 4477 4868
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Absolute dose values for normal tissue metrics for the two prostate cases are shown in 
Table 3-5.  Normal tissue metrics were within 3% of the baseline values for the simple prostate 
case, and did not change for the complex prostate case.  Resulting plans showed no significant 
dependence on allowing the gantry speed to vary during treatment.  
3.2.2 Maximum Gantry Speed
The maximum gantry speed was varied above and below that of the baseline plan (6 
deg/sec) to determine if a faster or slower rotation speed would improve or degrade the plan 
quality.  The resulting DHI and CI are graphed in Figures 3-7 to 3-9.  
Figure 3-7 shows that DHI values for the phantom were the lowest, and DHI values for 
the complex prostate PTV 1 were highest.  This was the case for all parameters studied.  The 
DHI for the phantom and simple prostate cases varied by less than 0.02 as the maximum gantry 
speed increased from 4 deg/sec to 12 deg/sec.  The variation in DHI for the baseline trial and 
DHI for 12 deg/sec trial for PTV1 was 0.026, and the 12 deg/sec trial performed best.  
Figure 3-7.  DHI for “Maximum Gantry Speed” parameter: 
phantom (green), simple prostate (red), and PTV 1 (blue) of 
complex prostate case.
35
The data in Figure 3-8 shows that the DHI values for PTV 3 and PTV 4 were much 
greater than the DHI values for PTV 1 and PTV 2.  This indicates that the dose to PTV 3 and 
PTV 4 was less homogeneous than the dose to PTV 1 and PTV 2.  
Resulting CI values are plotted for varying maximum gantry speed in Figure 3-9.  The 
variation in CI values across all maximum gantry speeds for the phantom and simple prostate 
Figure 3-8.  DHI for “Maximum Gantry Speed” parameter: 
PTV 1 (blue), PTV 2 (red), PTV 3 (green), and PTV 4 (purple) of 
complex prostate case.
Figure 3-9.CI for “Maximum Gantry Speed” parameter: 
phantom (green), simple prostate (red), and complex prostate 
(blue) cases.
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cases was less than 0.02.  The variation in CI values between the baseline trial and 12 deg/sec 
trial for the complex prostate case was 0.044, improving as the maximum gantry speed 
increased. 
Normal tissue metrics for variation of maximum gantry speed are plotted in Figure 3-10 
for the two prostate cases.  The normalized dose is plotted against the maximum gantry speed for 
all normal tissue metrics.  The two dotted lines represent 2% above and below the baseline dose 
value.  Dose values for all metrics were normalized to those of the baseline plan; therefore, all 
plots intersect at 6 deg/sec, the baseline setting for this parameter.  It is evident from the simple 
prostate graph that all variations for normal tissue dose metrics were within 2% of the baseline 
dose value.  The complex prostate normal tissue metrics varied more than 2% for some normal 
tissue metrics, but generally improved (lower dose) as the maximum allowable gantry speed 
increased.
3.2.3 Maximum Dose Rate
Figures 3-11 and 3-12 show DHI values plotted for the phantom case, simple prostate 
case, and complex prostate case.  Both continuously variable dose rates (circles) and discretely 
Figure 3-10.  Normal tissue metrics for “Maximum Gantry Speed” parameter for simple 
prostate and complex prostate cases.  All doses normalized to dose values for the baseline 
trial (6deg/sec).
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variable dose rates (triangles) are plotted for all PTVs.  As the maximum dose rate increased 
from 400 MU/min to 800 MU/min, the DHI values for the phantom, simple prostate, and 
PTV1of the complex prostate varied by less than 0.02 for both continuously variable and 
discretely variable dose rates.  Figure 3-12 shows DHI values for all PTVs of the complex 
prostate case.  The DHI values for PTV2 for 400 MU/min differed by 0.052 and 0.023 from the 
Figure 3-11.  DHI for “Maximum Dose Rate” parameter: 
phantom (green), simple prostate (red), and PTV 1 (blue) of 
complex prostate case.
Figure 3-12.  DHI for “Maximum Dose Rate” parameter: PTV 1 
(78 Gy, blue), PTV 2 (61.6 Gy, red), PTV 3 (56 Gy, green), and 
PTV 4 (46.2 Gy, purple) of complex prostate case.
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baseline DHI value (at 600 MU/min max) for discretely and continuously variable dose rates, 
respectively.  The DHI values for PTV3 varied by 0.026 and 0.039 for discretely and 
continuously variable dose rates, respectively.  The DHI for PTV4 varied by 0.042 and 0.029 for 
discretely and continuously variable dose rates, respectively.  For all maximum dose rates and all 
treatment sites shown, the DHI for the continuously variable dose rates differed from the DHI for 
the discretely variable dose rates by less than 0.025.  Only the DHI for PTV2 and PTV3 differed 
by more than 0.02 between continuous and discretely variable dose rates for the 600 MU/min 
maximum dose rate trials.
CI values for all maximum dose rates and all treatment sites are shown in Figure 3-13.  
CI for the phantom, simple prostate, and complex prostate cases varied by less than 0.02 over all 
maximum dose rates, both continuously and discretely variable.  For all maximum dose rates and 
all treatment sites shown, the CI for the continuously variable dose rates differed from the CI for 
the discretely variable dose rates by less than 0.02.
Figure 3-13.  CI for “Maximum Dose Rate” parameter: phantom 
(green), simple prostate (red), and complex prostate (blue)cases.
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Normal tissue metrics for maximum dose rate variation are shown in Table 3-9.  Dose 
values for all trials were normalized to the baseline plan.  For a given maximum dose rate, the 
difference in dose values between continuously variable dose rates and discretely variable dose 
rates was less than 3% for most metrics across both treatment sites.   The variation in dose to 
normal tissue metrics for changing maximum dose rates, however, was greater than 3% for 
every metric for the simple prostate case except for D25 of the bladder.  For the complex prostate 
case, only D50 for the bladder (800 continuous) and D10 for the right femoral head (400 discrete) 
had greater than a 3% variation from the baseline value.
3.2.4 Maximum MLC Leaf Speed
Figures3-14and 3-15 show the effect of varying maximum leaf speed on DHI for the 
phantom, simple prostate, and complex prostate cases.  As the maximum leaf speed was 
Table 3-9.  Normal tissue metrics for Dose Rate variations for simple and complex 
prostate cases.  All normal tissue dose metrics are normalized to baseline values.  
Maximum 
Dose Rate
Norm 
%
Rectum Bladder Rt. Femoral Head Lt. Femoral Head
D17 D35 D25 D50 D10 Dmax(1%) D10 Dmax(1%)
Simple Prostate
400 Disc* 95.7 1.053 1.058 1.021 1.033 0.897 0.922 0.971 0.997
400 Cont* 95.4 1.053 1.052 1.024 1.052 0.907 0.930 0.948 0.979
600 Disc 95.4 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
600 Cont 95.3 1.024 1.019 1.015 1.031 0.985 0.982 0.955 0.972
800 Disc 95.7 0.996 0.967 1.003 1.002 1.108 1.095 0.914 0.944
800 Cont 95.5 0.999 0.980 1.013 1.029 1.031 1.036 0.930 0.951
Complex Prostate
400 Disc 95 1.014 1.016 0.995 1.015 1.031 0.999 1.012 0.997
400 Cont 95.3 1.020 1.022 1.010 1.018 1.028 1.007 1.000 0.987
600 Disc 95 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
600 Cont 95.3 0.997 0.991 0.996 0.989 0.986 0.976 0.996 0.983
800 Disc 94.9 1.006 1.027 1.026 0.996 1.002 0.979 0.991 0.996
800 Cont 94.9 1.009 1.005 0.773 1.230 1.016 0.988 1.002 0.986
* Disc = discretely variable dose rate, Cont = continuously variable dose rate
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increased, the DHI for the phantom and simple prostate cases showed less than 0.02 variation
while PTV 1 of the complex prostate case showed a variation of 0.025 in DHI values between 
Figure 3-14.  DHI for “Maximum MLC Leaf Speed” 
parameter: phantom (green), simple prostate (red), 
and PTV 1 (blue) of complex prostate case.
Figure 3-15.  DHI for “Maximum MLC Leaf Speed” 
parameter: PTV 1 (78 Gy, blue), PTV 2 (61.6 Gy, 
red), PTV 3 (56 Gy, green), and PTV 4 (46.2 Gy, 
purple) of complex prostate case.
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2cm/sec and 3cm/sec maximum leaf speed.  DHI for PTV 1, PTV 2, and PTV 4 varied by 0.025, 
0.085 and 0.128, respectively, and generally improved as maximum leaf speed increased.  The 
DHI for PTV 3 varied by less than 0.02 among all maximum leaf speeds.  
CI for maximum leaf speed variation is plotted in Figure 3-16.  For the phantom and 
simple prostate cases, the CI varied by less than 0.02 across all maximum leaf speeds.  For the 
complex prostate case, the CI variation was 0.022, and the CI improved as maximum leaf speed 
increased.  
Normal tissue metrics for changing maximum MLC leaf speed are shown in Table3-10.  
All dose values are normalized to the baseline trial.  For the simple prostate case, metrics that 
exceeded a 3% variation in dose across all trials were D17 for the rectum, D25 for the bladder, and 
all metrics for the femoral heads.  Metrics that exceeded 3% variation for the complex prostate 
case were D17 for the rectum, both bladder metrics, and all metrics for the femoral heads except 
for Dmax(1%) for the right femoral head.  With only 2 exceptions, metrics for the rectum and 
Figure 3-16.  CI for “Maximum MLC Leaf Speed” 
parameter: phantom (green), simple prostate (red), and 
complex prostate (blue) cases.
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bladder performed worse than the baseline plan for both 1 cm/sec and 3 cm/sec trials, while 
metrics for the femoral heads performed better.
3.2.5 MLC Leaf Size
DHI and CI results for varying MLC size are shown in Table 3-11.  DHI values for the 
two leaf sizes for the phantom and simple prostate cases differed by less than 0.02.  The variation 
in DHI for PTV1, PTV2, and PTV4 of the complex prostate case was also less than 0.02, while 
the DHI value for PTV3 was 0.043 lower for 1cm leaf size.  
The difference in CI values for the two leaf sizes for phantom and simple prostate cases 
was less than 0.02.  The CI value for PTV1 was 0.03 greater for the 5mm leaf size.
Table 3-10.  Normal tissue metrics for Maximum MLC Leaf Speed variations for simple 
and complex prostate cases.  All normal tissue dose metrics are normalized to baseline 
values.
Max MLC 
Leaf Speed
Norm 
%
Rectum Bladder Rt. Femoral Head Lt. Femoral Head
D17 D35 D25 D50 D10 Dmax(1%) D10 Dmax(1%)
Simple Prostate
1 cm/sec 95.9 1.031 1.022 1.085 1.007 0.937 0.945 0.963 0.958
2 cm/sec 95.4 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
3 cm/sec 95.9 1.027 1.016 1.050 1.030 0.994 0.982 0.961 0.972
Complex Prostate
1 cm/sec 95.3 1.030 1.029 1.073 1.066 1.007 0.985 0.975 0.955
2 cm/sec 95 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
3 cm/sec 95 0.995 0.999 1.014 1.006 0.951 0.994 0.965 0.942
Table 3-11.  DHI and CI values for MLC Leaf Size (PTV 1: 78Gy, PTV 2: 
61.6Gy, PTV 3: 56Gy, PTV 4: 46.2Gy).
Dose Homogeneity Index
Leaf Size Phantom Simple Prostate
Complex Prostate
PTV 1 PTV 2 PTV 3 PTV 4
1 cm 0.0358 0.0736 0.1619 0.1274 0.6050 0.7379
5mm 0.0426 0.0768 0.1473 0.1068 0.6482 0.7091
Conformity Index
Leaf Size Phantom Simple Prostate Complex Prostate
1 cm 0.8777 0.9106 0.7900
5mm 0.8634 0.8946 0.8196
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Normal tissue metrics for the different MLC leaf sizes are shown in Table 3-12.  For the 
simple prostate case, dose metrics for the rectum and D25 for the bladder were less than 3% 
different between the two trials.  All other metrics differed by up to 10% and performed better 
for the 5mm leaf size.  For the complex prostate case, all metrics differed by more than 3% 
between the two trials except for D17 of the rectum.  The greatest discrepancy was about 8% for 
both metrics for the right femoral head.  Dose metrics for the complex prostate case performed 
better for the 5mm leaf size trial.
3.2.6 Maximum MU/degree
Two trials were run to investigate the effect of changing the maximum MU/degree: 100 
MU/deg and 1 MU/deg.  DHI and CI results are shown in Table 3-13.  Phantom and complex 
Table 3-12.  Normal tissue metrics for MLC Leaf Size variation for simple and 
complex prostate cases.  All normal tissue dose metrics are shown in cGy.
Leaf 
Size
Norm 
%
Rectum Bladder Rt. Femoral Head Lt. Femoral Head
D17 D35 D25 D50 D10 Dmax(1%) D10 Dmax(1%)
Simple Prostate
1 cm 95.4 3893 4420 1927 3702 3927 3855 4248 4248
5 mm 95.6 4014 4541 1965 3373 3800 3476 3815 4147
Complex Prostate
1 cm 95 6666 5066 6054 4811 4250 4748 4477 4868
5 mm 94.8 6627 4960 5810 4543 3937 4383 4239 4628
Table 3-13.  DHI and CI values for Maximum MU/degree (PTV 1: 78Gy, 
PTV 2: 61.6Gy, PTV 3: 56Gy, PTV 4: 46.2Gy).
Dose Homogeneity Index
MU/degree Phantom Simple Prostate
Complex Prostate
PTV 1 PTV 2 PTV 3 PTV 4
100 MU/deg 0.0358 0.0736 0.1619 0.1274 0.6050 0.7379
1 MU/deg 0.0358 0.0728 0.1619 0.1274 0.6050 0.7379
Conformity Index
MU/degree Phantom Simple Prostate Complex Prostate
100 MU/deg 0.8777 0.9106 0.7900
1 MU/deg 0.8777 0.9127 0.7900
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prostate cases showed identical resulting plans for this parameter, and the simple prostate case 
varied less than 0.02 for both DHI and CI.  Allowing only 1 MU/degree would result in a plan 
with a maximum of 360 MU for a 360 degree total arc length.  All resulting plans for 1MU/deg 
trials exceeded 360 MU.  The control point data was reviewed for these trials, and hand 
calculations for MU/degree verified that the treatment planning system ignored the 1 MU/deg 
limitation.
Normal tissue metrics for MU/degree trials are shown in Table 3-14.  Values for the 
simple prostate case varied less than 3% between trials.  
3.3 Planning Parameters
3.3.1 Beam Energy
Figures 3-17 and 3-18 are plots of the resulting DHI for energies of 6MV, 10MV, and 
15MV.  DHI values for the phantom and simple prostate cases varied by less than 0.02 for all 
three energies.  The difference in DHI for PTV1 between the 6MV trial and the 15MV trial was 
0.038, and the DHI performed better for lower energies.  The differences in DHI for PTV2, 
Table 3-14.Normal tissue metrics for Maximum MU/degree variations for simple and 
complex prostate cases.  All dose values are shown in cGy.
MU/degree Norm. %
Rectum Bladder Rt. Femoral Head Lt. Femoral Head
D17 D35 D35 D50 D10 Dmax(1%) D10 Dmax(1%)
Simple Prostate
100 MU/deg 95.4 5297 3893 4420 1927 3702 3927 3855 4248
1 MU/deg 95.5 5381 3930 4405 1963 3647 3877 3760 4147
Complex Prostate
100 MU/deg 95 6666 5066 6054 4811 4250 4748 4477 4868
1 MU/deg 95 6666 5066 6054 4811 4250 4748 4477 4868
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Figure 3-17.  DHI for “Beam Energy” parameter: phantom 
(green), simple prostate (red), and PTV 1 (blue) of complex 
prostate case.
Figure 3-18.  DHI for “Beam Energy” parameter: PTV 1 (78 
Gy, blue), PTV 2 (61.6 Gy, red), PTV 3 (56 Gy, green), and 
PTV 4 (46.2 Gy, purple) of complex prostate case.
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PTV3, and PTV4 (between the baseline DHI value and the DHI value with greatest variation 
from the baseline value) were 0.028, 0.038, and 0.071, respectively, and there was no consistent 
trend for DHI performance as beam energy increased.  
The CI for all treatment sites and all energies is shown in Figure 3-19.  The variation in 
CI across the three beam energies was 0.056, 0.022, and 0.07 for the phantom case, the simple 
prostate case, and the complex prostate case, respectively.  There was no common trend for 
target conformity as beam energy increased.  
Figure 3-19.  CI for “Beam Energy” parameter: phantom 
(green), simple prostate (red), and complex prostate (blue) 
cases.
Table 3-18.  Normal tissue metrics for Beam Energy variations for simple and complex 
prostate cases.  All normal tissue dose metrics are normalized to baseline values.
Beam 
Energy
Norm. 
%
Rectum Bladder Rt. Femoral Head Lt. Femoral Head
D17 D35 D25 D50 D10 Dmax(1%) D10 Dmax(1%)
Simple Prostate
6 MV 95.4 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
10 MV 96.1 0.986 0.915 1.036 1.020 1.078 1.091 1.038 1.034
15 MV 96.2 1.026 1.000 1.042 1.118 1.007 1.028 1.011 1.014
Complex Prostate
6 MV 95 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
10 MV 95.2 1.000 1.017 1.019 1.016 1.058 1.045 0.987 0.978
15 MV 95.2 1.011 1.035 1.008 0.995 1.120 1.060 1.017 1.016
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Normal tissue metrics for the three beam energies are shown in Table 3-18 for the simple 
and complex prostate cases, normalized to the baseline plan.  With few exceptions, the higher 
energies performed worse for sparing normal tissue, and most metrics had greater than 3% 
variation across all energies for both treatment sites.
3.3.2 Arc Length
DHI for varying arc lengths are shown in Figure 3-20 for the phantom, simple prostate, 
and PTV1 of the complex prostate.  DHI for varying arc lengths are shown in Figure 3-21 for all 
PTVs of the complex prostate case.  The DHI improved as the arc length increased for all PTVs. 
The larger arc lengths involved more control points, which allowed for better modulation of the 
dose to the target volume.  Pinnacle version 8.1y does not have double arc optimization 
capabilities,so 360 deg was the largest arc studied here.  From 60 to 180 degrees total arc length, 
there is an extreme improvement in DHI as arc length is increased.  Between 180 degrees and 
360 degrees total arc length, DHI continues to improve, but the rate of improvement is not as 
severe.  This is due to exit dose generated by the photon radiation.  The entire PTV is treated 
with a 180-degree arc, but a 360-degree arc allows for improvement in dose homogeneity. 
Figure 3-20.  DHI for “Arc Length” parameter: phantom 
(green), simple prostate (red), and PTV 1 (blue) of 
complex prostate case.
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The CI for arc length trials are plotted in Figure 3-22.  As expected, the CI also improved 
as arc length increased because more control points allowed for better conformity of the
prescription dose to the PTV.  The rate of improvement in CI also declined at 180 degrees total 
arc length.
Normal tissue metrics for arc length variations are shown in Figure 3-23.  For the smaller 
arc lengths, normal tissue sparing depended greatly on how the arc was oriented.  With the 
Figure 3-21.  DHI for “Arc Length” parameter: PTV 1 
(78 Gy, blue), PTV 2 (61.6 Gy, red), PTV 3 (56 Gy, 
green), and PTV 4 (46.2 Gy, purple) of complex prostate 
case.
Figure 3-22.  CI for “Arc Length” parameter: phantom 
(green), simple prostate (red), and complex prostate 
(blue) cases.
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exception of the femoral heads, which were partly spared for smaller arcs, normal tissue sparing 
improved as arc length increased.
3.3.3 Collimator Angle
The collimator angle was varied from 0 to 90 degrees for all treatment sites.  For the 
phantom case, the baseline collimator angle was 90 degrees.  For both the simple and complex 
prostate cases, the baseline collimator angle was 0 degrees.  Figures 3-24 and 3-25 show the DHI 
values for all three treatment sites for all collimator angles studied.  The DHI variation across all 
collimator angles for the phantom case was less than 0.02.  The greatest variation in DHI values 
all collimator angles for the simple prostate case was 0.027.  For the complex prostate case, 
changing collimator angle had the biggest effect on the DHI for PTV4, where DHI values varied 
by 0.294 from a collimator angle of 0 degrees to a collimator angle of 90 degrees.  PTV1, PTV2, 
and PTV3 had DHI variations of 0.047, 0.061, and 0.062, respectively.  
Figure 3-23.Normal tissue metrics for “Arc Length” parameter for simple prostate and 
complex prostate cases.  All doses normalized to dose values for the baseline trial (360 deg).
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CI for collimator angle variations are shown in Figure 3-26.  The CI values for the 
phantom and the simple prostate cases varied across all collimator angles by 0.059 and 0.069, 
respectively.  The largest variation in CI values was 0.127 for the PTV1 of the complex prostate 
case.  
Figure 3-24.  DHI for “Collimator Angle” parameter: 
phantom (green), simple prostate (red), and PTV 1 (blue) of 
complex prostate case.
Figure 3-25.  DHI for “Collimator Angle” parameter: PTV 1 
(78 Gy, blue), PTV 2 (61.6 Gy, red), PTV 3 (56 Gy, green), and 
PTV 4 (46.2 Gy, purple) of complex prostate case.
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Normal tissue metrics for the simple and complex prostate cases are plotted against
collimator angle in Figure 3-27.  Metrics for the simple prostate case generally varied more than 
metrics for the complex prostate case.  The simple prostate case had fewer optimization goals 
and constraints than the complex prostate case, allowing the optimization more room to diverge 
from the baseline plan.  For the simple prostate case, D50 for the bladder varied over 40% by 
changing the collimator from 0 degrees to 90 degrees.  All other metrics, except for the left 
femoral head varied between 17% and 25% from 0 to 90 degrees.  The most variation from the 
Figure 3-26.  CI for “Collimator Angle” parameter: 
phantom (green), simple prostate (red), and complex 
prostate (blue) cases.
Figure 3-27.  Normal tissue metrics for “Collimator Angle” parameter for simple prostate 
and complex prostate cases.  All doses normalized to dose values for the baseline trial (360 
deg).
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baseline plan for the complex prostate case was 12% for D25 for the bladder with a collimator 
angle of 60 degrees.
3.3.4 Dose Grid Resolution
Trials were run for 0.3cm, 0.4cm, and 0.5cm resolution.  Figures 3-28 and 3-29 show 
DHI values for the phantom, simple prostate, and complex prostate cases.  For the complex 
prostate case, only dose grid resolutions of 0.4cm and 0.5cm were used due to software failures 
Figure 3-28.  DHI for “Dose Grid Resolution” 
parameter: phantom (green), simple prostate (red), and 
PTV 1 (blue) of complex prostate case.
Figure 3-29.  DHI for “Dose Grid Resolution” 
parameter: PTV 1 (78 Gy, blue), PTV 2 (61.6 Gy, red), 
PTV 3 (56 Gy, green), and PTV 4 (46.2 Gy, purple) of 
complex prostate case.
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of the treatment planning system.  The variation in DHI values across all dose grid resolutions 
for the phantom case was less than 0.02.  The variation in DHI values for the simple prostate 
case was only 0.021.  The difference in DHI values between both dose grid resolutions for PTV1 
and PTV2 of the complex prostate case was less than 0.02, while the difference in DHI values 
for PTV3 and PTV4 between both dose grid resolutions was 0.023 and 0.060, respectively.
The CI for all treatment sites is plotted against the dose grid resolution in Figure 3-30.  
The variation in CI values was 0.050 for the phantom case and 0.031for the simple prostate case. 
Figure 30.CI for “Dose Grid Resolution” parameter: 
phantom (green), simple prostate (red), and complex 
prostate (blue) cases.
Table 3-19. Normal tissue metrics for Dose Grid Resolution  variations for simple and 
complex prostate cases.  All normal tissue dose metrics are normalized to baseline 
values (0.4cm).
Dose Grid 
Resolution
Norm 
%
Rectum Bladder Rt. Femoral Head Lt. Femoral Head
D17 D35 D25 D50 D10 Dmax(1%) D10 Dmax(1%)
Simple Prostate
0.3 cm 95.3 0.970 0.968 1.034 1.070 0.928 0.979 0.967 0.965
0.4 cm 95.4 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
0.5 cm 95.4 1.054 1.062 1.056 1.061 0.940 1.015 0.932 0.935
Complex Prostate
0.4 cm 95 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
0.5 cm 95 1.013 1.001 1.036 1.013 0.930 0.933 0.832 0.907
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A dose grid resolution of 0.3cm provided the worst CI for both the phantom and simple prostate 
cases.   The two CI values for the complex prostate case differed by less than 0.02.
Normal tissue metrics for dose grid resolution variation are shown in Table 3-19, 
normalized to the baseline values.  All metrics for the simple prostate case and most metrics for 
the complex prostate case showed greater than 3% variation from the baseline values.  The dose 
to both rectum metrics and to D50 of the bladder varied by less than 3% between the 0.5cm trial 
and the baseline trial for the complex prostate case.
3.3.5 Final Gantry Spacing
The setting for final gantry spacing determines the spacing of control points around the 
final arc.  The options for final gantry spacing were 2, 3, 4, or 6 degrees.  It is recommended in 
the literature to start with a spacing of 4 degrees (RaySearch Laboratories, 2009). DHI values 
are shown for all spacing options for all treatment sites in Figures 3-31 and 3-32.  Trials with 2 
Figure 3-31.  DHI for “Final Gantry Spacing” parameter: 
phantom (green), simple prostate (red), and PTV 1 (blue) of 
complex prostate case.
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and 3 degrees final spacing could not be run for the complex prostate case due to software 
failures of the treatment planning system.  For the phantom case, the variation in DHI values 
across all final gantry spacing options was less than 0.02.  The variation in DHI values for the 
simple prostate case was less than 0.02 for 2, 3, and 4 degrees final gantry spacing, but for 6 
degree final gantry spacing, the DHI increased by 0.027 from the baseline value (4 degrees).  
Similarly, the DHI value for 6 degree final gantry spacing for PTV1 of the complex prostate case 
was 0.030 higher than the baseline, and the DHI value for 6 degree final gantry spacing for 
PTV3 was 0.028.  The difference in DHI values for PTV2 and PTV4 was less than 0.02 between 
4 and 6 degrees final gantry spacing trials.  
The CI values for final gantry spacing trials are shown in Figure 3-33.  Similar to the DHI 
plots, the variation in CI values for the phantom and simple prostate cases remained less than 
0.02 for 2, 3, and 4 degree final gantry spacing.  The difference in CI values between 4- degree 
final gantry spacing and 6-degree final gantry spacing was 0.049 for the phantom case, 0.032 for 
the simple prostate case, and 0.117 for the complex prostate case.  Target conformity was worst 
Figure 3-32.  DHI for “Final Gantry Spacing” 
parameter: PTV 1 (78 Gy, blue), PTV 2 (61.6 Gy, red), 
PTV 3 (56 Gy, green), and PTV 4 (46.2 Gy, purple) of 
complex prostate case.
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for 6 degree final gantry spacing for all treatment sites, most dramatically for the complex 
prostate.
All normal tissue metrics for final gantry spacing variations are shown in Table 3-20, 
normalized to the baseline values (4 degrees).  For the simple prostate case, 6-degree final gantry 
spacing, all metrics showed greater than 3% difference from the baseline plan except Dmax(!%) for 
both femoral heads.  The only other metrics that showed greater than 3% difference from the 
Figure 3-33.  CI for “Final Gantry Spacing” parameter: 
phantom (green), simple prostate (red), and complex 
prostate (blue) cases.
Table 3-20.  Normal tissue metrics for Final Gantry Spacing  variations for simple and 
complex prostate cases.  All normal tissue dose metrics are normalized to baseline 
values (4 deg).
Final 
Gantry 
Spacing
Norm 
%
Rectum Bladder Rt. Femoral Head Lt. Femoral Head
D17 D35 D25 D50 D10 Dmax(1%) D10 Dmax(!%)
Simple Prostate
2 deg 95.9 0.993 0.965 0.997 1.024 1.020 1.022 1.005 1.034
3 deg 95.5 1.003 0.978 0.992 0.983 0.985 0.997 0.981 1.009
4 deg 95.4 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
6 deg 95.2 1.061 1.048 1.040 0.929 0.935 0.980 0.955 0.997
Complex Prostate
4 deg 95 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
6 deg 95 1.031 1.064 1.012 1.019 1.071 1.016 1.023 0.999
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baseline values for the simple prostate case were D35 of the rectum, and Dmax(!%) of the left 
femoral head for 2 degree final gantry spacing.  For the complex prostate case, 6 degree final 
gantry spacing, both rectum metrics and D10 of the right femoral head showed greater than 3% 
difference from the baseline values.
3.3.6 Maximum Delivery Time
The data collected in this study for maximum delivery time was based on the user-
requested maximum delivery time, not the actual delivery time estimated by Pinnacle after 
optimization.  Table 3-21 shows both the input maximum delivery times (user-requested) and 
estimated delivery times for the three treatment sites.  Trials were run for all treatment sites with 
60-second, 120-second, and 240-second maximum delivery times, along with intermediate 
maximum delivery times that were different for each treatment geometry.  
The data for DHI values for different maximum delivery times is shown in Figures 3-34 
and 3-35.  The phantom case resulted in identical plans for both 20-second maximum delivery 
time and 45-second maximum delivery time.  The actual estimated delivery time for both plans 
was approximately 60 seconds, indicating that the 20-second and 45-second limitations were 
rejected by the treatment planning system for those trials.  The variation in DHI values for all 
other trials for the phantom case were within 0.02 of the baseline DHI value (120 seconds).  The 
Table 3-21. Input maximum delivery time and estimated delivery time for all trials, all 
treatment sites.
Phantom Simple Prostate Complex Prostate
Input (sec) Est. Delivery (sec) Input (sec) Est. Delivery (sec) Input (sec) Est. Delivery (sec)
20 60 20 60 -- --
45 60 -- -- -- --
60 60 60 60 60 64
-- -- 90 88 -- --
120 98 120 110 120 119
-- -- -- -- 150 143
240 194 240 211 240 194
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variation in DHI values for the simple prostate case remained within 0.02 of the baseline DHI 
values for 20-second, 60-second, and 90-second trials.  The DHI value for the 240-second trial 
for the simple prostate case, however, was 0.028 greater than the DHI for the baseline trial.  For 
the simple prostate case, the longest maximum delivery time requested resulted in worse dose 
homogeneity across the PTV.  DHI values for the 60-second and 150-second trials for PTV1 of 
the complex prostate case were within 0.02 of the baseline DHI value, but the DHI value for the 
240-second trial was 0.028 less than the baseline value.  For PTV1 of the complex prostate case, 
Figure 3-35.  DHI for “Maximum Delivery Time” 
parameter: PTV 1 (78 Gy, blue), PTV 2 (61.6 Gy, red), 
PTV 3 (56 Gy, green), and PTV 4 (46.2 Gy, purple) of 
complex prostate case.
Figure 3-34.  DHI for “Maximum Delivery Time” 
parameter: phantom (green), simple prostate (red), 
and PTV 1 (blue) of complex prostate case.
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the longer maximum delivery time resulted in better dose homogeneity across the target volume.  
DHI values for all PTVs of the complex prostate case are plotted in Figure 3-35.  The DHI for 
the 60-second trial for PTV2 differed by 0.028 from the baseline trial, while DHI values for all 
other trials for PTV2 were within 0.02 of the baseline DHI value.  For PTV3, the 150-second 
trial resulted in a DHI value 0.032 greater than the baseline DHI value.  DHI values for PTV4 
were mostly within 0.02 variation from the baseline plan, but the DHI for the 60-second trial was 
0.051greater.
The CI as a function of maximum delivery time is shown in Figure 3-36.  All trials for 
the phantom case resulted in a variation of CI values of less than 0.02 from the baseline CI value 
(120 seconds).  CI values for the simple prostate case were within 0.02 of the baseline value for 
the 20-second, 60-second, and 90-second trials, but the CI value for the 240-second trial was 
0.036 lower than the CI value for the baseline trial.  All CI values for the complex prostate case 
were within 0.02 of the baseline CI value.  
Normal tissue metrics for varying maximum delivery time are plotted in Figure3-37, 
normalized to the baseline trial.  For the simple prostate case, the right femoral head received 
Figure 3-36.  CI for “Maximum Delivery Time” 
parameter: phantom (green), simple prostate (red), and 
complex prostate (blue) cases.
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greater dose as the maximum delivery time increased, but both rectum metrics received less dose 
for greater maximum delivery times.  The left femoral head showed no trend as requested 
delivery timed increased, but performed worst for the baseline trial.  The bladder metrics showed 
no consistent trend, but were lowest for the baseline trial.  For the complex prostate case, all 
normal tissues generally performed better for longer maximum delivery times, with the 
exception of the femoral heads.
3.4 Monitor Units and Delivery Time
Two of the most advertised advantages of VMAT treatments are monitor unit and time 
efficiency. Table 3-22 shows the monitor units and estimated delivery time per fraction for each 
trial and each treatment geometry in this study.  In general, the phantom case required the fewest 
MU and had the shortest fractional treatment times, while the the complex prostate case required 
the most MU and had the longest fractional treatment times.  The phantom case also showed the 
least variation in MU and treatment times for any given parameter, while the complex prostate 
showed the most.  
Figure 3-37.  Normal tissue metrics for “Maximum Delivery Time” parameter for simple 
prostate and complex prostate cases.  All doses normalized to dose values for the baseline 
trial (120 sec).
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The original fixed-beam IMRT plan for the simple prostate patient required 719 
MU/fraction.  The estimated delivery time for this patient was between 8 and 11 minutes.  The 
baseline VMAT plan (with comparable plan quality) required 34% fewer MU and 77% less time 
to deliver than the original IMRT plan for the simple prostate case.  The complex prostate patient 
was originally treated with tomotherapy and required MU is unknown.
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Table 3-22.  MU and estimated delivery times for all parameters, trials, and treatment 
sites.  All baseline trials are shown in bold.
Parameter Trial
Phantom Simple Prostate Complex Prostate
MU Delivery Time MU
Delivery 
Time MU
Delivery 
Time
Gantry speed variability yes 329 98 478 110 826 119
no 329 98 474 114 826 119
Maximum Gantry Speed 6 deg/sec 329 98 478 110 826 119
4 deg/sec 329 97 479 110 805 117
8 deg/sec 329 95 477 109 837 116
12 deg/sec 329 95 476 109 845 117
Maximum Dose Rate Disc 600 329 98 478 110 826 119
Cont 600 329 98 474 113 812 119
Disc 400 329 99 455 117 737 121
Cont 400 329 97 461 120 705 120
Disc 800 329 99 488 110 791 99
Cont 800 329 97 482 106 789 106
Maximum MLC Leaf Speed 2 cm/sec 329 98 478 110 826 119
3 cm/sec 329 98 469 112 763 115
1 cm/sec 329 98 439 107 722 115
MLC size 1 cm 329 98 478 110 826 119
0.5 cm 332 105 449 99 870 118
Maximum MU/degree 100 MU/deg 329 98 478 110 826 119
1 MU/deg 329 98 473 107 826 119
Beam Energy 6 MV 329 98 478 110 826 119
10 MV 279 112 407 113 855 118
15 MV 266 98 387 107 760 115
Arc Length 60 deg 384 109 506 120 930 129
120 deg 355 112 379 122 935 140
180 deg 345 100 463 106 924 115
270 deg 329 105 402 108 804 117
360 deg 329 98 478 110 826 119
Collimator Angle 0 deg 331 97 478 110 826 119
30 deg 331 107 432 106 737 119
45 deg 336 104 442 114 772 127
60 deg 334 98 402 113 841 118
90 deg 329 98 399 122 756 119
Dose Grid Resolution 0.4 cm 329 98 478 110 826 119
0.3 cm 334 120 506 113 -- --
0.5 cm 329 97 458 110 832 121
Final Gantry spacing 4 deg 329 98 478 110 826 119
2 deg 329 98 493 108 -- --
3 deg 329 103 481 106 -- --
6 deg 332 120 460 83 665 96
Maximum Delivery Time 120 sec 329 98 478 110 826 119
60 sec 330 60 424 60 618 64
240 sec 329 194 482 211 892 194
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4 DISCUSSION
In this study, we varied several parameters independently for 3 treatment geometries of 
increasing complexity to determine their effect on resulting plan quality for VMAT treatment 
planning.  We found that most parameters had a small effect (<0.02 variation from baseline 
values) on DHI and CI for both phantom and simple prostate cases and a larger effect (>0.02 
variation from baseline values) on DHI and CI for the complex prostate case.  Even though 
greater than 0.02 variation from baseline DHI and CI values was found for most parameters for 
the complex prostate case, the data was inconclusive of predictable trends for varying any 
parameters other than total arc length.  Similarly, the normal tissue metrics showed less than 3% 
change for most parameters for the simple prostate case and greater than 3% change for the 
complex prostate case with few predictable trends.
We observed that in effect, one can use a wide variety of values for any set of parameters 
with very little change in the resulting plans for non-complex cases.  In some instances, this is 
because parameters are subject to an override by Pinnacle (i.e. maximum delivery time, 
maximum gantry speed).  We also speculate that because all parameters are optimized together, 
there are enough degrees of freedom built into VMAT optimization to compensate for any one 
parameter that would otherwise cause the optimization algorithm to struggle (i.e. maximum 
gantry speed, maximum MLC leaf speed).  This was especially true when varying 
commissioning parameters for the two non-complex cases.  For these reasons we have 
determined that for non-complex treatment sites, SmartArc optimization is largely user-input-
independent and hardware independent, whereas complex treatment sites show a greater 
dependency on input parameter values.
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4.1 Comparison to Previous Literature
Literature concerning how varying certain parameters affects the resulting plan quality is 
limited.  Su et al. used DMPO optimization for fixed-beam IMRT treatments to study the effects 
of varying leaf width from 5mm to 1cm on resulting plan quality and accuracy (Su et al. 2007).  
They concluded that leaf width showed no significant difference in CI or DHI for head and neck, 
prostate, or spine geometries, but that there was slightly better dose accuracy for 1cm leaves.  
Our study showed similar results for CI and DHI; all but one PTV (PTV3 of the complex 
prostate case) had DHI changes of less than 2%, and the greatest difference in CI was only 3% 
for the complex prostate case.  The issue of beam energy has also been studied previously for 
IMRT treatments.  Pirzkall et al. showed that prostate IMRT treatments with less than 9 fields 
could result in dose increases in tissues distant to the target volume (i.e. near the skin surface) for 
lower energies (6MV), even though PTV and avoidance structure metrics were the same for 6, 
10, and 18MV.  Studies have also shown that with a greater number of fields (>9), the difference 
between dose distributions for different beam energies disappears (Pirzkall et al. 2002; Fox et al.
2008).  We found that there was no identifiable trend for increasing beam energy of VMAT 
plans, but significant changes were seen in the DHI values of the complex prostate PTVs and the 
CI and normal tissue metrics for all treatment geometries.  However, we speculate that the 
effects of beam energy may not translate directly from fixed-beam IMRT to VMAT treatment 
plans, as the beam shape modulation is more restricted for VMAT planning.  
While previous studies focus on one or two parameters of interest, we conducted a 
systematic one dimensional examination of all the major VMAT parameters (commissioning and 
planning) for geometries of varying complexity.  This allowed us to provide information 
comparing capabilities of different machines and different vendors.  This study concludes that 
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two major differences between Varian and Elekta machines (MLC leaf width and continuously 
or discretely variable dose rates) are largely inconsequential. 
4.2 Limitations and Future Work
There were several limitations to this study. First, only one parameter was varied at a 
time, while all the others were held fixed.  Possible interdependencies between the parameters 
might have a larger effect on resulting plan quality if multiple parameters were changed 
simultaneously.  For example, the beam shape modulation between control points depends on 
both the maximum MLC leaf speed and the maximum gantry speed.  Varying several parameters 
at once to study their combined effects on resulting plan quality could be valuable future 
research.  This could be done by randomly sampling a multi-dimensional complex space, as it 
would be impossible to vary all parameters systematically (over 800,000 possible combinations 
for the parameter values varied in this study).  
In addition to varying multiple parameters together, it would be beneficial to investigate 
how changing parameters effects plan accuracy, not just resulting plan quality.  While this study 
thoroughly investigated how each parameter effects the resulting DHI, CI, and dose metrics 
calculated internally by the treatment planning system, it remains unknown how well the 
calculated doses match what is actually being delivered by the treatment machine.  
4.3 Clinical Relevance
Since the time this study was done, a clinical version (9.0) of Pinnacle including the 
SmartArc module has been released, improving upon the research version (8.1y) by including 
double arc capabilities and allowing the jaws to move with the MLC to provide additional 
collimation.  To check the clinical validity of the plans created using the research version, test 
plans for the complex prostate case were run on Pinnacle 9.0.  A new baseline plan was created 
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on Pinnacle 9.0 that provided dose values equal to or better than those provided by the 8.1y 
baseline plan.  Trials were run for 4 degree and 6 degree final gantry spacing using Pinnacle 9.0, 
and compared to the 4 degree and 6 degree trials run on Pinnacle 8.1y.  The results for DHI and 
CI for both versions of Pinnacle are shown in Table 4-1.  The change in DHI from 4 degree final 
gantry spacing to 6 degree final gantry spacing is similar for the research and clinical versions of 
Pinnacle.  The CI showed a change for the research version, but not for the clinical version.  The 
CI also performed better for the clinical version of Pinnacle.
4.4 Optimization Noise
We considered a 0.02 variation in DHI or CI values to be a significant change, and a 3% 
difference in normal tissue metrics to be a significant change.  These increments were based on 
what we determined to be clinically significant changes.  In other words, changes of this 
magnitude would make one plan favorable to another in a clinical setting.  In order to assess a 
statistically significant difference, it was necessary to determine the uncertainty in the 
optimization algorithm, or "optimization noise."  To do this, very small changes were made to 
the baseline plans for each treatment geometry, either to the original optimization goals or to the 
dose grid resolution.  These slightly modified plans were re-optimized and the doses re-
computed.  The trials for determining optimization noise by modifying an optimization goal are 
described in Table 4-2.  Dose grid resolution was also slightly modified to determine 
optimization noise and dose calculation uncertainty.  In trials 6 and 7 for the phantom, simple 
Table 4-1.  DHI and CI results for varying final gantry spacing on the research (8.1y) 
and clinical (9.0) versions of Pinnacle.
Version Trial DHI (PTV1) DHI (PTV 2) DHI (PTV 3) DHI (PTV 4) CI
8.1y
4 deg 0.16 0.13 0.61 0.74 0.79
6 deg 0.19 0.11 0.63 0.75 0.67
9.0
4 deg 0.15 0.11 0.57 0.77 0.83
6 deg 0.18 0.12 0.61 0.79 0.83
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prostate, and complex prostate cases, the dose grid resolution was changed to 0.401cm and 
0.399cm, respectively, from the original resolution of 0.400cm.  After the dose grid resolution 
was modified for trials 6 and 7, plans were re-optimized and the dose was re-computed.  The 
dose grid resolution for trials 8 and 9 was modified similarly to trials 6 and 7, but the plans were 
not re-optimized – only the dose was recomputed.  Trials 6 and 7 are meant to show a combined 
effect of optimization noise and dose calculation uncertainty, while trials 8 and 9 only show the 
dose calculation uncertainty.  Table 4-3 describes trials 6 through 9.  
Results for determining optimization noise are shown in Table 4-4.  Metrics used in the 
study for all PTVs (DHI and CI) were normalized to the baseline values.  The table shows the 
difference between the values for DHI and CI for each trial and the baseline DHI and CI values
(EFGH%&'(%EIHJ.  For trials 2-5 for all treatment geometries, the differences in DHI and CI were 
Table 4-2.  Description of trials used to determine optimization noise by modifying an 
optimization goal.
Geometry Trial Weight ROI Type Original Goal New Goal
Phantom
Trial 2 10 PTV Max Dose 205 204
Trial 3 10 PTV Max Dose 205 206
Simple Prostate
Trial 2 45 PTV Min DVH 7600 7601
Trial 3 45 PTV Min DVH 7600 7599
Complex Prostate
Trial 2 25 4620 only Uniform 4620 4621
Trial 3 25 4620 only Uniform 4620 4619
Trial 4 100 PTV 1 Uniform 7800 7801
Trial 5 100 PTV 1 Uniform 7800 7799
Table 4-3.  Description of trials used to determine optimization noise and dose 
calculation uncertainty by modifying the dose grid resolution.
Geometry Trial Re-optimization?
Original Dose Grid 
Resolution (cm)
New Dose Grid 
Resolution (cm)
Phantom, Simple Prostate, 
Complex Prostate
Trial 6 yes 0.400 0.401
Trial 7 yes 0.400 0.399
Trial 8 no 0.400 0.401
Trial 9 no 0.400 0.399
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less than 0.002, the criteria for clinical significance.  For trials 6 and 7 (re-optimization and re-
calculation of dose), the greatest difference in DHI was 0.04, and the greatest difference in CI 
was 0.03.  The average of all numbers in trials 6 and 7 was 0.013, which is less than the value for 
clinical significance.  DHI and CI values for trials 8 and 9 (no re-optimization) showed no 
difference from the baseline DHI and CI values.  Though there is undoubtedly both optimization 
noise and dose calculation uncertainty in the treatment planning system, we determined that the 
values for optimization and dose calculation uncertainty are less than our criteria for clinical 
significance.
Table 4-4.  Results for optimization noise.  Values represent the change in DHI and CI 
values from the baseline values for each trial.
Trial
Phantom Simple Prostate Complex Prostate
!DHI !CI !DHI !CI PTV1 PTV2 PTV3 PTV4
!DHI !CI !DHI !DHI !DHI
Baseline 0.00 0.00 0.00 0.00 0.0 0.0 0.0 0.0 0.0
2 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00
3 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.00 0.00
4 -- -- -- -- 0.01 0.02 0.00 0.02 0.00
5 -- -- -- -- 0.00 0.02 0.00 0.00 0.00
6 0.00 0.01 0.02 0.03 0.00 0.01 0.03 0.01 0.01
7 0.00 0.00 0.01 0.01 0.01 0.01 0.04 0.02 0.02
8 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
9 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
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5 CONCLUSIONS
In conclusion, we used the Pinnacle SmartArc treatment planning module to 
systematically examine the effects of varying parameters on resulting VMAT treatment plans.  
The study was intentionally robust, allowing us to answer our initial hypothesis in a clinically 
relevant way.  We were able to create better than ±3% dose homogeneity in the PTV of a 
phantom, and better than ±5% dose homogeneity in the PTV of a simple prostate patient for a 
wide range of input parameter values, while keeping treatment times better than half of 
corresponding fixed-beam IMRT plans.  We were unable to achieve better than ±5% dose 
homogeneity in the primary PTV of a complex prostate patient, though the baseline plan we 
created was clinically acceptable and treatment times were still less than half of standard fixed-
beam IMRT treatments.  We found that SmartArc is largely user-independent and machine 
hardware-independent for non-complex treatment geometries, but significant changes (>0.02 
variation from baseline values for DHI and CI and >3% variation from baseline values for 
normal tissue metrics) in plan quality can be seen when varying parameters for complex 
geometries.  This is useful information for centers when implementing protocols for VMAT 
treatment planning or investigating which vendor provides the most compatible machine 
hardware to their facility.  
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